- Home
- VIR
as 03-12-2025 4:00pm EST
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.4B | IPO Year: | 2019 |
| Target Price: | $34.83 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.56 - $14.45 | Next Earning Date: | 05-01-2025 |
| Revenue: | $74,205,000 | Revenue Growth: | -13.90% |
| Revenue Growth (this year): | -63.21% | Revenue Growth (next year): | 17.69% |
Stock Insider Trading Activity of Vir Biotechnology Inc. (VIR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| de Verneuil Vanina | VIR | EVP and General Counsel | Feb 26 '25 | Sell | $9.14 | 7,373 | $67,402.49 | 79,460 | |
| SCANGOS GEORGE A | VIR | Director | Feb 24 '25 | Sell | $9.45 | 10,056 | $95,063.39 | 698,239 | |
| HANLY ANN M. | VIR | EVP & Chief Technology Officer | Feb 24 '25 | Sell | $9.45 | 14,168 | $133,935.77 | 117,901 | |
| De Backer Marianne | VIR | Chief Executive Officer | Feb 22 '25 | Sell | $9.45 | 16,122 | $152,407.71 | 849,217 | |
| de Verneuil Vanina | VIR | EVP and General Counsel | Feb 22 '25 | Sell | $9.45 | 5,140 | $48,590.48 | 79,460 | |
| Sabatini Brent | VIR | SVP, Chief Accounting Officer | Feb 22 '25 | Sell | $9.45 | 1,562 | $14,766.21 | 46,627 | |
| SCANGOS GEORGE A | VIR | Director | Feb 18 '25 | Sell | $9.81 | 10,964 | $107,575.48 | 698,239 | |
| Sabatini Brent | VIR | SVP, Chief Accounting Officer | Feb 13 '25 | Sell | $9.15 | 1,562 | $14,291.36 | 46,627 | |
| SATO VICKI L | VIR | Director | Jan 8 '25 | Sell | $12.52 | 10,960 | $137,219.20 | 1,312,391 |
Latest Vir Biotechnology Inc. News
VIR Breaking Stock News: Dive into VIR Ticker-Specific Updates for Smart Investing
Argus Research
8 days ago
VIR: Lowering target price to $9.00
Simply Wall St.
12 days ago
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
Thomson Reuters StreetEvents
13 days ago
Q4 2024 Vir Biotechnology Inc Earnings Call
GuruFocus.com
14 days ago
Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Zacks
14 days ago
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
Business Wire
14 days ago
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Argus Research
15 days ago
VIR: Rating increased to a HOLD
Business Wire
21 days ago
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
Compare VIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIR Vir Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.